CHL
MCID: LYM133
MIFTS: 75

Lymphoma, Hodgkin, Classic (CHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphoma, Hodgkin, Classic

MalaCards integrated aliases for Lymphoma, Hodgkin, Classic:

Name: Lymphoma, Hodgkin, Classic 57 75 38 40
Hodgkin Lymphoma 57 12 76 53 37 29 13 6 15
Hodgkin Disease 57 12 53 75 55 43 73
Hodgkin's Lymphoma 38 12 53 15
Chl 57 75
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 73
Hodgkin's Disease of Intrapelvic Lymph Nodes 73
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 12
Stage I Subdiaphragmatic Hodgkin Lymphoma 12
Lymphoma, Hodgkin, Susceptibility to 40
Hodgkin Lymphoma, Susceptibility to 57
Classic Hodgkin Lymphoma 59
Classic Hodgkin Disease 59
Lymphoma, Hodgkin's 53
Hodgkin's Sarcoma 12
Hodgkins Lymphoma 12
Hodgkin's Disease 76
Hl 12

Characteristics:

Orphanet epidemiological data:

59
classic hodgkin lymphoma
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
lymphoma, hodgkin, classic:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lymphoma, Hodgkin, Classic

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 98293Disease definitionHodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.EpidemiologyHL is an uncommon cancer with an incidence of about 1/40,000 in North America and Europe. There are about 8500 new cases reported in the U.S. each year.Clinical descriptionHL is comprised of 2 major forms: classical Hodgkin lymphoma (CHL; see this term), seen in 95% of all HL cases, and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL; see this term), seen in only 5% of all HL cases. Disease onset occurs most frequently in young adults (age 15-35) followed by older adults (over the age of 55) and usually begins with the painless swelling of a lymph node in the upper body. Disease can spread to multiple lymph node regions or lymphoid structures and associated systemic symptoms (weight loss > 10% of baseline, fevers, night sweats) are observed in about 20% of patients.EtiologyThe exact cause is unknown but immunological, genetic and environmental factors are thought to be involved.Management and treatmentTreatment with radiotherapy and systemic chemotherapy leads to a very good prognosis. Follow-up physical exams, blood tests and x-rays are needed to check for recurrence and check for any long-term side effects of the toxic treatments. Possible long-term side effects include secondary cancers, infertility, reduced immunity, thyroid problems, heart disease and stroke.PrognosisThe international prognostic score (IPS) is a score given based on the presence of 7 risk factors (male sex, >45 years of age, stage 4 disease, serum albumin 15,000/mm3) at the time of diagnosis. The more factors present, the less favorable the prognosis. The cure rates are 90% for early-stage HL and 70% for advance stage HL.Visit the Orphanet disease page for more resources.

MalaCards based summary : Lymphoma, Hodgkin, Classic, also known as hodgkin lymphoma, is related to nodular lymphocyte predominant hodgkin lymphoma and hodgkin's lymphoma, lymphocytic depletion. An important gene associated with Lymphoma, Hodgkin, Classic is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Viral carcinogenesis. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are hyperhidrosis and ataxia

Disease Ontology : 12 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

OMIM : 57 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000)

MedlinePlus : 43 Hodgkin disease is a type of lymphoma. Lymphoma is a cancer of a part of the immune system called the lymph system. The first sign of Hodgkin disease is often an enlarged lymph node. The disease can spread to nearby lymph nodes. Later it may spread to the lungs, liver, or bone marrow. The exact cause is unknown. Hodgkin disease is rare. Symptoms include Painless swelling of the lymph nodes in the neck, armpits, or groin Fever and chills Night sweats Weight loss Loss of appetite Itchy skin To diagnose Hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. Treatment depends on how far the disease has spread. It often includes radiation therapy or chemotherapy. The earlier the disease is diagnosed, the more effective the treatment. In most cases, Hodgkin disease can be cured. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 75 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

Wikipedia : 76 Hodgkin''s lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white... more...

Related Diseases for Lymphoma, Hodgkin, Classic

Diseases related to Lymphoma, Hodgkin, Classic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 649)
# Related Disease Score Top Affiliating Genes
1 nodular lymphocyte predominant hodgkin lymphoma 34.1 BCL6 PAX5
2 hodgkin's lymphoma, lymphocytic depletion 32.9 PAX5 PTPRC
3 hodgkin's lymphoma, lymphocytic-histiocytic predominance 32.8 BCL6 PTPRC
4 diffuse large b-cell lymphoma 32.6 BCL6 CD5 MIR155 MIR21
5 primary central nervous system lymphoma 32.5 BCL6 PAX5
6 lymphoma, mucosa-associated lymphoid type 32.4 BCL6 CD19 CD5 SMUG1
7 plasmablastic lymphoma 32.3 BCL6 PTPRC
8 reticulosarcoma 31.9 BCL6 PAX5 PTPRC
9 intraocular lymphoma 30.9 BCL6 PAX5
10 lymphosarcoma 30.8 BCL6 CD22 CD5 MIR20A PTPRC SMUG1
11 myeloma, multiple 30.5 CD19 PTPRC PVT1 SMUG1
12 prostate lymphoma 30.3 CD5 SMUG1
13 mantle cell lymphoma 30.3 BCL6 CD19 CD5 PAX5 PTPRC
14 lymphoma 30.2 BCL6 KLHDC8B PAX5 PVT1
15 autoimmune lymphoproliferative syndrome, type v 30.2 BCL6 CD5
16 bone lymphoma 30.1 BCL6 CD22 SMUG1
17 burkitt lymphoma 30.1 BCL6 MIR155 PAX5 PVT1
18 splenic marginal zone lymphoma 30.1 BCL6 CD5 PAX5
19 dermatomyositis 30.0 MIR155 MIR21
20 cll/sll 30.0 CD5 PAX5
21 melanoma 30.0 MIR140 MIR200A MIR30B MIR374A PVT1
22 b-cell lymphomas 30.0 BCL6 CD5 MIR20A PAX5 PVT1
23 plasma cell neoplasm 29.9 CD19 PTPRC PVT1
24 nonalcoholic fatty liver disease 29.8 MIR140 MIR200A MIR21
25 leukemia, acute myeloid 29.8 CD19 CD22 MIR155 MIR21 MIR374A PTPRC
26 lymphoblastic lymphoma 29.8 BCL6 CD5 PTPRC
27 intravascular large b-cell lymphoma 29.7 BCL6 CD5
28 lymphoma, non-hodgkin, familial 29.7 BCL6 CD19 CD22 CD5 PAX5 PTPRC
29 multicentric castleman disease 29.7 BCL6 PAX5
30 glioma 29.7 MIR140 MIR20A MIR21 PVT1
31 breast lymphoma 29.7 BCL6 CD5 SMUG1
32 gamma heavy chain disease 29.5 CD19 PTPRC
33 hepatocellular carcinoma 29.5 MIR155 MIR186 MIR18A MIR200A MIR20A MIR21
34 ovarian cancer 29.4 MIR140 MIR155 MIR200A MIR21 MIR374A PVT1
35 composite lymphoma 29.4 BCL6 CD5 PAX5
36 leukemia, acute lymphoblastic 29.4 CD19 MIR155 MIR21 PAX5
37 lung cancer 29.3 MIR140 MIR155 MIR18A MIR200A MIR20A MIR21
38 leukemia, chronic lymphocytic 29.0 BCL6 CD19 CD5 MIR140 PAX5 PTPRC
39 classic hodgkin lymphoma, mixed cellularity type 12.3
40 classic hodgkin lymphoma, lymphocyte-rich type 12.3
41 hodgkin lymphoma, during pregnancy 12.3
42 non-hodgkin lymphoma, during pregnancy 12.3
43 hodgkin lymphoma, childhood 12.1
44 non-hodgkin lymphoma, childhood 12.1
45 hepatic lipase deficiency 12.1
46 hodgkin's lymphoma, nodular sclerosis 11.8
47 hodgkin's lymphoma, mixed cellularity 11.7
48 hydrolethalus syndrome 1 11.7
49 t-cell/histiocyte rich large b cell lymphoma 11.7
50 cutaneous t cell lymphoma 11.6

Graphical network of the top 20 diseases related to Lymphoma, Hodgkin, Classic:



Diseases related to Lymphoma, Hodgkin, Classic

Symptoms & Phenotypes for Lymphoma, Hodgkin, Classic

Symptoms via clinical synopsis from OMIM:

57
Lab:
polyclonal elevation of igm
impaired lymphocyte transformation with phytohemagglutinin

Heme:
hodgkin disease


Clinical features from OMIM:

236000

Human phenotypes related to Lymphoma, Hodgkin, Classic:

59 32 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 frequent (33%) Frequent (79-30%) HP:0000975
2 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
3 respiratory insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0002093
4 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
5 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
6 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
7 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
8 bone marrow hypocellularity 59 32 occasional (7.5%) Occasional (29-5%) HP:0005528
9 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
10 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
11 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
12 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
13 migraine 59 32 occasional (7.5%) Occasional (29-5%) HP:0002076
14 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
15 cellular immunodeficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0005374
16 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
17 skin rash 59 32 occasional (7.5%) Occasional (29-5%) HP:0000988
18 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
19 bone pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002653
20 lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002665
21 osteolysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002797
22 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
23 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
24 dyspnea 32 occasional (7.5%) HP:0002094
25 immunodeficiency 32 hallmark (90%) HP:0002721
26 neoplasm 59 Occasional (29-5%)
27 headache 32 occasional (7.5%) HP:0002315
28 polyclonal elevation of igm 32 HP:0003459
29 hodgkin lymphoma 32 HP:0012189
30 impaired lymphocyte transformation with phytohemagglutinin 32 HP:0003347

Drugs & Therapeutics for Lymphoma, Hodgkin, Classic

FDA approved drugs:

(show top 50) (show all 68)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Afinitor 18 49 EVEROLIMUS Novartis March 2009
3
Akynzeo 18 49 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
4
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
5
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
6
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
7
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
8
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
9
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
10
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
11
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
12
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
13
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
14
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
15
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
16
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
17
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
18
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
19
Iressa 18 49 GEFITINIB AstraZeneca May 2003
20
Ixempra 18 49 IXABEPILONE Bristol-Myers Squibb October 2007
21
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
22
Lazanda 18 FENTANYL CITRATE Archimedes June 2011
23
Lupron Depot 18 49 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
24
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
25
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
26
Picato gel 18 INGENOL MEBUTATE LEO Pharma January 2012
27
Plenaxis 18 ABARELIX Praecis Pharmaceuticals December 2003
28
Provenge 18 49 sipuleucel-T Dendreon May 2010
29
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
30
Sancuso 18 GRANISETRON ProStrakan September 2008
31
Self-examination breast pad 18 Inventive Products on December 22, 1995
32
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
33
Synercid I.V. 18 DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN Rhone Poulenc Rorer September 1999
34
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
35
Tasigna 18 49 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
36
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
37
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
38
Trelstar Depot/ Trelstar LA 18 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm June 2000/ June 2001
39
Valchlor 18 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
40
Vandetanib 18 49 vandetanib AstraZeneca April 2011
41
Xofigo 18 49 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
42
Zoladex 18 49 GOSERELIN ACETATE AstraZeneca January 1996
43
Zuplenz 18 ONDANSETRON Strativa Pharmaceuticals July 2010
44
Zykadia 18 49 CERITINIB Novartis April 2014
45
Aldurazyme 18 LARONIDASE Genzyme May 2003
46
Allegra 18 FEXOFENADINE HYDROCHLORIDE Hoechst Marion Roussel July 1996
47
Avelox I.V. 18 MOXIFLOXACIN HYDROCHLORIDE Bayer November 2001
48
Biaxin XL 18 CLARITHROMYCIN Abbott Laboratories March 2000
49
Cedax 18 CEFTIBUTEN DIHYDRATE Schering-Plough December 1995
50
Cefazolin and Dextrose USP 18 CEFAZOLIN SODIUM B Braun Medical July 2000

Drugs for Lymphoma, Hodgkin, Classic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 525)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
2
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 241903 13342
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
9
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
10
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
11
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
12
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
13
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antilymphocyte Serum Phase 4,Phase 2,Phase 1,Not Applicable
39 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Mitogens Phase 4,Phase 2,Phase 1,Not Applicable
43
Bleomycin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 11056-06-7 5360373
44
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
45
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-22-7, 2068-78-2 5978
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
47
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
48
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
49
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
50
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093

Interventional clinical trials:

(show top 50) (show all 1067)
# Name Status NCT ID Phase Drugs
1 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
2 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
3 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
6 A Safety Study of Growth Factor Use in Treatment With Brentuximab Vedotin Plus Chemotherapy Recruiting NCT03646123 Phase 4 brentuximab vedotin;doxorubicin;vinblastine;dacarbazine;G-CSF
7 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
8 Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
9 Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
10 Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma Unknown status NCT00025636 Phase 3 carmustine;cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan;methotrexate;vincristine sulfate
11 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Unknown status NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
12 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
13 Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
14 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
15 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
16 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
17 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
18 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
19 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
20 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) Completed NCT01034163 Phase 3 Panobinostat;Placebo
21 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
22 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
23 Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
24 High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients Completed NCT00784537 Phase 2, Phase 3 ABVD;ABVD and Radiotherapy
25 Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
26 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
27 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
28 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
29 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
30 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
31 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF
32 Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
33 SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
34 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
35 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
36 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
37 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
38 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
39 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
40 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
41 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
42 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
43 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
44 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
45 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
46 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
47 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
48 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
49 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
50 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng

Search NIH Clinical Center for Lymphoma, Hodgkin, Classic

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Hodgkin, Classic cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Hodgkin, Classic

Genetic tests related to Lymphoma, Hodgkin, Classic:

# Genetic test Affiliating Genes
1 Hodgkin Lymphoma 29 KLHDC8B

Anatomical Context for Lymphoma, Hodgkin, Classic

MalaCards organs/tissues related to Lymphoma, Hodgkin, Classic:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Breast, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Hodgkin, Classic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Hodgkin, Classic

Articles related to Lymphoma, Hodgkin, Classic:

(show top 50) (show all 3451)
# Title Authors Year
1
A role for surgery in the treatment of relapsed Hodgkin lymphoma. ( 30294914 )
2019
2
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
3
Multimodality imaging in endomyocardial fibrosis associated with Hodgkin lymphoma. ( 29529276 )
2018
4
Paraneoplastic pemphigus without detectable anti-plakin antibodies in a patient with non-Hodgkin lymphoma. ( 29143865 )
2018
5
Classic Hodgkin lymphoma with osseous involvement mimicking Langerhans cell histiocytosis in a child. ( 29307624 )
2018
6
Calciphylaxis in a Patient With Non-Hodgkin Lymphoma: Case Report and Literature Review. ( 29478335 )
2018
7
Chemotherapy-Colchicine Interaction in a Child with Familial Mediterranean Fever and Hodgkin Lymphoma. ( 29531656 )
2018
8
Reduced Mortality Risk in the Recent Era in Early-Stage Hodgkin Lymphoma Patients Treated With Radiation Therapy With or Without Chemotherapy. ( 29153331 )
2018
9
Coping With Knife: Postoperative Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29413265 )
2018
10
Long-term follow-up of 2 patients treated with <sup>90</sup> Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29719928 )
2018
11
Concurrent mucosa-associated lymphoid tissue lymphoma with diffuse large B-cell lymphoma transformation and Hodgkin lymphoma of the neck. ( 29427189 )
2018
12
Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. ( 29449276 )
2018
13
Primary Cardiac B-Non-Hodgkin Lymphoma Disguised as a Pacemaker Endocarditis. ( 29977733 )
2018
14
Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India. ( 29893471 )
2018
15
Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29401099 )
2018
16
Second primary cutaneous T-cell lymphoma in patients with non-Hodgkin lymphoma: a chicken-or-the-egg issue. ( 29047113 )
2018
17
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29537344 )
2018
18
Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127. ( 29351228 )
2018
19
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )
2018
20
Testicular Estrogen-Secreting Leydig Cell Tumor in 18F-FDG PET/CT: An Incidental Detection in a Patient Treated by Chemotherapy for Hodgkin Lymphoma. ( 29166332 )
2018
21
Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. ( 28332735 )
2018
22
Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival. ( 29479868 )
2018
23
Hodgkin Lymphoma With Multiple Autoimmune Disorders: Case Report and Review of the Literature. ( 29980411 )
2018
24
Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma. ( 28679297 )
2018
25
The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor. ( 29373571 )
2018
26
Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. ( 29351986 )
2018
27
Ruxolitinib significantly enhances <i>in vitro</i> apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. ( 29515770 )
2018
28
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. ( 29978452 )
2018
29
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. ( 29449275 )
2018
30
Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29309302 )
2018
31
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group<sup/>. ( 29979097 )
2018
32
CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). ( 29950528 )
2018
33
Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome. ( 28760045 )
2018
34
Hemophagocytic Lymphohistiocytosis Secondary to Unknown Underlying Hodgkin Lymphoma Presenting with a Cholestatic Pattern of Liver Injury. ( 29805352 )
2018
35
Non-alcoholic Wernicke-Korsakoff syndrome heralding non-Hodgkin lymphoma progression. ( 29582179 )
2018
36
Palisading neutrophilic and granulomatous dermatitis as a presentation of Hodgkin lymphoma: A case and review. ( 29226345 )
2018
37
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma. ( 29377256 )
2018
38
Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma? ( 29650494 )
2018
39
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. ( 28971503 )
2018
40
Classical Hodgkin lymphoma-type and monomorphic-type post-transplant lymphoproliferative disorder following liver transplantation: a case report. ( 29980871 )
2018
41
Herpes simplex reactivation after photodynamic therapy for actinic cheilitis in a patient with Non-Hodgkin Lymphoma: a possible indication for prophylaxis. ( 29512976 )
2018
42
Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma. ( 29767440 )
2018
43
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. ( 30122950 )
2018
44
The histological, immunohistochemical and genetic features of classical Hodgkin lymphoma and anaplastic large cell lymphoma with aberrant T-cell/B-cell antigen expression. ( 30339972 )
2018
45
Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma. ( 30430604 )
2018
46
An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma. ( 28659618 )
2018
47
Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B cell lymphoma or classical Hodgkin lymphoma: a histologic diagnostic pitfall. ( 30370547 )
2018
48
Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: report on a rare infectious complication and a review of the literature. ( 30238855 )
2018
49
Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma. ( 29469175 )
2018
50
Comparing causes of death of Hodgkin lymphoma and breast cancer patients between medical records and cause-of-death statistics. ( 30425583 )
2018

Variations for Lymphoma, Hodgkin, Classic

ClinVar genetic disease variations for Lymphoma, Hodgkin, Classic:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh37 Chromosome 3, 49209095: 49209095
2 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh38 Chromosome 3, 49171662: 49171662

Cosmic variations for Lymphoma, Hodgkin, Classic:

9 (show all 35)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 20
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 20
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 20
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 20
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 20
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 20
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 20
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 20
10 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 20
11 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 20
12 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 20
13 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 20
14 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 20
15 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 20
16 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 20
17 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 20
18 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 20
19 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 20
20 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 20
21 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 20
22 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 20
23 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 20
24 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
25 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
26 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
27 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 20
28 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 20
29 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 20
30 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 20
31 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 20
32 COSM5761 CTNNB1 skin,neck,malignant melanoma,nodular c.131C>T p.P44L 3:41224643-41224643 4
33 COSM476 BRAF skin,neck,malignant melanoma,nodular c.1799T>A p.V600E 7:140753336-140753336 4
34 COSM584 NRAS skin,arm,malignant melanoma,nodular c.182A>G p.Q61R 1:114713908-114713908 3
35 COSM580 NRAS skin,arm,malignant melanoma,nodular c.181C>A p.Q61K 1:114713909-114713909 3

Copy number variations for Lymphoma, Hodgkin, Classic from CNVD:

7 (show top 50) (show all 204)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma

Expression for Lymphoma, Hodgkin, Classic

Search GEO for disease gene expression data for Lymphoma, Hodgkin, Classic.

Pathways for Lymphoma, Hodgkin, Classic

Pathways related to Lymphoma, Hodgkin, Classic according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 Viral carcinogenesis hsa05203
3 Epstein-Barr virus infection hsa05169

GO Terms for Lymphoma, Hodgkin, Classic

Cellular components related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MIR140 MIR155 MIR186 MIR18A MIR20A MIR21
2 micro-ribonucleoprotein complex GO:0035068 9.28 MIR140 MIR155 MIR186 MIR200A MIR20A MIR21

Biological processes related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 miRNA mediated inhibition of translation GO:0035278 9.58 MIR155 MIR20A MIR21
2 negative regulation of stress fiber assembly GO:0051497 9.49 MIR20A MIR21
3 positive regulation of cardiac muscle hypertrophy GO:0010613 9.48 MIR155 MIR21
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.46 MIR20A MIR21
5 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.43 MIR140 MIR21
6 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.37 MIR155 MIR20A
7 positive regulation of activated T cell proliferation GO:0042104 9.33 MIR155 MIR21 MIR30B
8 regulation of B cell receptor signaling pathway GO:0050855 9.32 PAX5 PTPRC
9 gene silencing by miRNA GO:0035195 9.32 MIR140 MIR155 MIR186 MIR18A MIR200A MIR20A
10 positive regulation of vascular smooth muscle cell differentiation involved in phenotypic switching GO:1905932 9.26 MIR140 MIR18A
11 negative regulation of regulatory T cell differentiation GO:0045590 9.13 MIR155 MIR21 MIR30B

Molecular functions related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR140 MIR155 MIR18A MIR200A MIR20A MIR21

Sources for Lymphoma, Hodgkin, Classic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....